ABBV-969 Dual-Targeting

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

ABBV-969 Dual-Targeting

Apr 30, 2025, 03:55 | Blog

Ingo Hartung: ABBV-969 Dual-Targeting STEAP1 and PSMA ADC Shows Translational Promise with TOPi Payload

Ingo Hartung, Executive Director, Head of Medicinal Chemistry and Drug Design at Merck Healthcare, posted…

All: 1 Posts: 1 - 100

'

ASCO 2025 for Trainees and Residents: Your Ultimate Guide to Success

'

ctDNA after surgery for MMRd tumors can prevent cancer recurrence - Yelena Janjigian at AACR25

'

Top Growing Medical Universities in the Post-Soviet Region – BIGR 2025 Edition

'

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab

'

POEM 2025 Scientific Meeting: Key Sessions, Workshops, and Why You Should Attend

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023